NO950518L - Anvendelse av terpenforbindelser for redusert frigjöring av arachidonsyre og bestemmelsesmediatorer - Google Patents

Anvendelse av terpenforbindelser for redusert frigjöring av arachidonsyre og bestemmelsesmediatorer

Info

Publication number
NO950518L
NO950518L NO950518A NO950518A NO950518L NO 950518 L NO950518 L NO 950518L NO 950518 A NO950518 A NO 950518A NO 950518 A NO950518 A NO 950518A NO 950518 L NO950518 L NO 950518L
Authority
NO
Norway
Prior art keywords
pct
terpene compounds
mediators
assay
compounds
Prior art date
Application number
NO950518A
Other languages
English (en)
Other versions
NO950518D0 (no
NO313814B1 (no
Inventor
Uwe R Juergens
Original Assignee
Uwe R Juergens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19934319556 external-priority patent/DE4319556C2/de
Priority claimed from DE4319554A external-priority patent/DE4319554C2/de
Application filed by Uwe R Juergens filed Critical Uwe R Juergens
Publication of NO950518D0 publication Critical patent/NO950518D0/no
Publication of NO950518L publication Critical patent/NO950518L/no
Publication of NO313814B1 publication Critical patent/NO313814B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
NO19950518A 1993-06-13 1995-02-10 Anvendelse av terpenforbindelser for fremstilling av medikamenter for behandling av bronkial astma NO313814B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19934319556 DE4319556C2 (de) 1993-06-13 1993-06-13 Verwendung von 1,8-Cineol zur entzündungshemmenden Behandlung von steroidpflichtigem Asthma bronchiale
DE4319554A DE4319554C2 (de) 1993-06-13 1993-06-13 Verwendung von Menthol zur peroralen entzündungshemmenden Behandlung von Asthma bronchiale
PCT/EP1994/001900 WO1994028895A2 (de) 1993-06-13 1994-06-11 Verwendung von terpenverbindungen zur verminderten freisetzung von arachidonsäure und entzündungsmediatoren

Publications (3)

Publication Number Publication Date
NO950518D0 NO950518D0 (no) 1995-02-10
NO950518L true NO950518L (no) 1995-02-10
NO313814B1 NO313814B1 (no) 2002-12-09

Family

ID=25926728

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19950518A NO313814B1 (no) 1993-06-13 1995-02-10 Anvendelse av terpenforbindelser for fremstilling av medikamenter for behandling av bronkial astma

Country Status (19)

Country Link
US (1) US5889049A (no)
EP (1) EP0654994B1 (no)
JP (1) JPH08500612A (no)
AT (1) ATE173622T1 (no)
AU (1) AU680663B2 (no)
BG (1) BG62474B1 (no)
BR (1) BR9405404A (no)
CA (1) CA2140660A1 (no)
CZ (1) CZ285025B6 (no)
DE (1) DE59407336D1 (no)
DK (1) DK0654994T3 (no)
ES (1) ES2126123T3 (no)
HU (1) HUT69684A (no)
NO (1) NO313814B1 (no)
PL (1) PL308539A1 (no)
RO (1) RO111989B1 (no)
RU (1) RU2161482C2 (no)
SK (1) SK282308B6 (no)
WO (1) WO1994028895A2 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693654B1 (fr) * 1992-07-20 1994-08-26 Oreal Médicament, notamment immunomodulateur, contenant des enveloppes ou fractions d'enveloppes de bactéries filamenteuses non photosynthétiques et non fructifiantes, et sa préparation.
SE9604751D0 (sv) * 1996-12-20 1996-12-20 Astra Ab New therapy
GB2329583A (en) * 1997-09-25 1999-03-31 Marilyn Rydstrom Use of tea-tree oil for prophylaxis against cystitis
CN1125651C (zh) 1998-04-16 2003-10-29 欧维塔有限公司 新颖的、含有存在于大高良姜中的芳族化合物与萜类化合物的协同组合物
US6420435B1 (en) 1999-11-01 2002-07-16 Joe S. Wilkins, Jr. Method for treating gastrointestinal disorders
US6733794B1 (en) * 1999-12-17 2004-05-11 Edward L. Ingram Topical composition for antiseptic and analgesic purposes
US7041706B2 (en) * 2002-04-19 2006-05-09 Wilkins Jr Joe S Method for treating crohn's disease
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
EP2647372A1 (de) 2008-09-04 2013-10-09 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH Monoterpene für die Behandlung von Atemwegserkrankungen, insbesondere bronchopulmonalen Erkrankungen
DE102010022174A1 (de) 2010-05-12 2011-11-17 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue Darreichungsformen für Cineol
DE202010007074U1 (de) 2010-05-12 2011-08-12 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue Darreichungsformen für Cineol
CN103328506A (zh) * 2010-10-15 2013-09-25 米迪缪尼有限公司 用于改善肺功能的疗法
TR201808978T4 (tr) * 2011-02-11 2018-07-23 Zx Pharma Llc Çok partiküllü l-mentol formülasyonları ve ilgili yöntemler.
DE202012000910U1 (de) 2012-01-20 2013-01-21 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Systemische Darreichungsformen mit kontrollierter Freisetzung und verbesserter Stabilität
JP2012131823A (ja) * 2012-03-12 2012-07-12 Lotte Co Ltd 線毛運動活性化剤及びそれを含む飲食品

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4103019A (en) * 1975-10-07 1978-07-25 Laboratorios Landerlan, S. A. Triterpene derivatives
JP2524709B2 (ja) * 1985-09-26 1996-08-14 塩野義製薬株式会社 鎮痛消炎作用増強剤
US5120538A (en) * 1990-02-05 1992-06-09 Pt Darya-Varia Laboratoria Combinations of compounds isolated from curcuma spp as anti-inflammatory agents
AU7570191A (en) * 1990-03-14 1991-10-10 Board Of Regents, The University Of Texas System Tripterygium wilfordii hook f extracts and components thereof for immunosuppression
US5580562A (en) * 1990-03-14 1996-12-03 Board Of Regents The University Of Texas System Preparations and uses thereof for immunosuppression
US5616458A (en) * 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
JPH0426619A (ja) * 1990-05-18 1992-01-29 Lotte Co Ltd 抗アレルギー剤および抗アレルギー剤を含有する食品添加物
AU1783092A (en) * 1991-04-08 1992-11-02 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Inhibitors of protein kinase c function
US5322689A (en) * 1992-03-10 1994-06-21 The Procter & Gamble Company Topical aromatic releasing compositions
DE4211745A1 (de) * 1992-04-03 1993-10-07 Boerner Gmbh Verwendung von Propolis und/oder seinen Fraktionen
US5338758A (en) * 1992-04-03 1994-08-16 Schering Corporation Bicyclic diterpene PAF antagonist compounds
US5527890A (en) * 1993-04-16 1996-06-18 Glycomed Incorporated Derivatives of triterpenoid acids and uses thereof
US5464754A (en) * 1993-08-17 1995-11-07 The Regents Of The University Of California Assay and substrate for arachidonoyl-specific phospholipase A2
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds

Also Published As

Publication number Publication date
HU9500714D0 (en) 1995-04-28
BG62474B1 (bg) 1999-12-30
SK30395A3 (en) 1995-11-08
WO1994028895A2 (de) 1994-12-22
WO1994028895A3 (de) 1995-04-06
SK282308B6 (sk) 2002-01-07
US5889049A (en) 1999-03-30
HUT69684A (en) 1995-09-28
NO950518D0 (no) 1995-02-10
CZ37095A3 (en) 1995-11-15
CA2140660A1 (en) 1994-12-22
CZ285025B6 (cs) 1999-05-12
EP0654994B1 (de) 1998-11-25
EP0654994A1 (de) 1995-05-31
AU680663B2 (en) 1997-08-07
RO111989B1 (ro) 1997-04-30
ES2126123T3 (es) 1999-03-16
ATE173622T1 (de) 1998-12-15
DE59407336D1 (de) 1999-01-07
BG99499A (bg) 1995-12-29
DK0654994T3 (da) 1999-08-09
JPH08500612A (ja) 1996-01-23
PL308539A1 (en) 1995-08-21
RU2161482C2 (ru) 2001-01-10
AU7000394A (en) 1995-01-03
BR9405404A (pt) 1999-05-25
NO313814B1 (no) 2002-12-09

Similar Documents

Publication Publication Date Title
NO950518L (no) Anvendelse av terpenforbindelser for redusert frigjöring av arachidonsyre og bestemmelsesmediatorer
MY109862A (en) A short infusion methods for administration of paclitaxel
ZA908777B (en) Oral composition for the treatment of inflammatory bowel diseases
NO951000L (no) Fremgangsmåte for reduksjon av blodnivåer av totalt kolesterol og lavdensitets lipoprotein-kolesterol
NO20010844L (no) Regulering av substrataktivitet
WO2001017517A3 (en) Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer
IS8187A (is) Meðferð á fráhvarfseinkennum
ES2144119T3 (es) Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada.
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
Naim et al. Effects of oral stimulation on the cephalic phase of pancreatic exocrine secretion in dogs
KR940018089A (ko) 내부조직의 방사선 손상에 대한 예방 및 처치방법
EP1093816A3 (en) Use of ST1435 in hormonal therapy by transdermal application
TJ286B (en) A method for treatment or prevention of obesity
Auguste et al. Effect of verapamil on the gastric mucosal level of PGE2 during stress
RU2043104C1 (ru) Болеутоляющее средство при хроническом панкреатите
NO974956L (no) Terapeutisk sammensetning for artritis
WO2001001995A3 (en) Method for treatment of asthma syndrome
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
WO2003024394A3 (en) Method of treating benign prostatic hyperplasia and other beingn porstate conditions
RU2043103C1 (ru) Средство, уменьшающее внешнесекреторную недостаточность поджелудочной железы при хроническом панкреатите
WO2001028566B1 (en) Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia
Schettino et al. A mild form of captopril-induced pemphigus
GB2033748A (en) A thiol derivative for the treatment of cellulitis
UA37528A (uk) Спосіб профілактики післяопераційних ускладнень у дітей після тонзилектомії
UA36361A (uk) Спосіб лікування захворювань щитовидної залози

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees